- Home
- NRIX vs HBNC Comparison
NRIX vs HBNC Comparison
Compare NRIX & HBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- HBNC
- Stock Information
- Founded
- NRIX 2009
- HBNC 1873
- Country
- NRIX United States
- HBNC United States
- Employees
- NRIX N/A
- HBNC N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- HBNC Major Banks
- Sector
- NRIX Health Care
- HBNC Finance
- Exchange
- NRIX Nasdaq
- HBNC Nasdaq
- Market Cap
- NRIX 728.6M
- HBNC 706.4M
- IPO Year
- NRIX 2020
- HBNC N/A
- Fundamental
- Price
- NRIX $9.91
- HBNC $16.65
- Analyst Decision
- NRIX Strong Buy
- HBNC Buy
- Analyst Count
- NRIX 15
- HBNC 3
- Target Price
- NRIX $29.13
- HBNC $19.67
- AVG Volume (30 Days)
- NRIX 733.8K
- HBNC 515.8K
- Earning Date
- NRIX 10-10-2025
- HBNC 10-22-2025
- Dividend Yield
- NRIX N/A
- HBNC 3.84%
- EPS Growth
- NRIX N/A
- HBNC 170.74
- EPS
- NRIX N/A
- HBNC 1.17
- Revenue
- NRIX $88,381,000.00
- HBNC $211,582,000.00
- Revenue This Year
- NRIX $74.59
- HBNC $47.63
- Revenue Next Year
- NRIX N/A
- HBNC $4.03
- P/E Ratio
- NRIX N/A
- HBNC $14.24
- Revenue Growth
- NRIX 41.86
- HBNC 19.27
- 52 Week Low
- NRIX $8.18
- HBNC $12.70
- 52 Week High
- NRIX $29.56
- HBNC $19.18
- Technical
- Relative Strength Index (RSI)
- NRIX 47.82
- HBNC 58.87
- Support Level
- NRIX $8.97
- HBNC $16.46
- Resistance Level
- NRIX $9.68
- HBNC $16.93
- Average True Range (ATR)
- NRIX 0.55
- HBNC 0.38
- MACD
- NRIX 0.04
- HBNC 0.07
- Stochastic Oscillator
- NRIX 55.13
- HBNC 82.84
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.